### Antibodies

<table>
<thead>
<tr>
<th>What is it?</th>
<th>What could it do?</th>
<th>Key Facts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered in a clinic setting over a period of 30 minutes or more.</td>
<td>Laboratory-made broadly neutralizing antibodies (bNAbS) against HIV could provide protection against infection in HIV-negative people.</td>
<td>bNAbs are isolated from the blood of people living with HIV. A handful of individuals make these potent immune responses.</td>
</tr>
<tr>
<td>An alternative approach using vectors and genes that can be turned into 'antibody factories' within the body is also under investigation.</td>
<td>It might be possible to formulate these bNAbS so that a single dose could provide protection for months at a time.</td>
<td>The most potent bNAbS come from months of co-evolution with virus during chronic infection. They have unique characteristics.</td>
</tr>
<tr>
<td>Both infusion and gene therapy approaches differ from immunization with vaccines that teach the body how to make its own defenses.</td>
<td>Testing bNAbS for HIV prevention can also provide proof-of-concept for developing HIV vaccine candidates.</td>
<td>Some have atypically long regions in the CDR43 loop—a portion of the &quot;arms&quot; of the Y-shaped antibody protein. Others undergo a lengthy process of maturation to become potent against HIV. It will take a long time to create vaccines that elicit such responses.</td>
</tr>
<tr>
<td>Product Name(s)</td>
<td>Phase of Research</td>
<td>Research Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>3BNC117</td>
<td>Phase I</td>
<td>Phase I trial in HIV-negative people and people living with HIV looking at safety, tolerability and virologic impact associated with different doses found safety in all groups and sustained viral load reductions at the highest dose. Further treatment and prevention studies are planned.</td>
</tr>
<tr>
<td>AAV vector encoding PG9 antibody</td>
<td>Phase I</td>
<td>Ongoing Phase I trial is establishing safety and optimal doses of a gene-therapy approach to passive immunization.</td>
</tr>
<tr>
<td>CAP256-VRC26</td>
<td>Pre-clinical</td>
<td>Targeting the V1V2 binding site in development for treatment and prevention, currently in preclinical phase.</td>
</tr>
<tr>
<td>Ibalizumab (TMB-355)</td>
<td>Phase I, II</td>
<td>Ibalizumab has completed Phase I and II trials in HIV-negative individuals and people living with HIV. It is currently available for treatment (as part of combination therapy) via compassionate access programs.</td>
</tr>
<tr>
<td>PGT121</td>
<td>Pre-clinical</td>
<td>Targets the V3 region of gp120 and has shown potency in reducing viral load in SIV-infected non-human primates. It is being developed as a possible treatment and/or a component of a cure strategy for people living with HIV.</td>
</tr>
<tr>
<td>VRC01</td>
<td>Phase I</td>
<td>Targets the gp120 binding site recently being evaluated in a dose escalation study looking at safety, acceptability, PK and PD in people living with HIV. Preliminary results have been reported showing an impact on viral load. HVTN 104 is phase I trial evaluating safety and drug levels of this antibody in HIV-negative adults. Concept note for follow-on efficacy trial has been developed. Phase I safety trial in infants is also being explored. Planned treatment trials will look at VRC01 + ART in acute infection. Additional trials in HIV-positive and -negative individuals are planned.</td>
</tr>
</tbody>
</table>
## What is it?

**Long-Acting Injectable (LAI) Antiretrovirals (ARVs)**

- Antiretroviral drugs given via injection that persist in the blood for long periods of time.
- LAI ARVs need to be dosed every few months. Single-drug LAI PrEP regimens being evaluated utilize injections (one in each buttock) every eight to 12 weeks.
- Two-drug LAI treatment regimens being evaluated utilize injections every four or eight weeks.

## What could it do?

- In HIV-positive people, LAI ARVs could simplify treatment and change the way ARVs are delivered.
- In HIV-negative people, the same ARVs could be long-acting PrEP. This could reduce the burden of adherence and make it easier for some people to take, although issues of regular testing to monitor for HIV infection need to be addressed, as they do for all PrEP strategies (right now PrEP is a daily oral strategy).

## Key Facts

- Trials of LAI ARVs start with a lead-in phase where people take oral formulations of the same drugs to establish safety and tolerability in a formulation that can be discontinued. (Injectable ARVs cannot be removed from the body.)
- The drugs used as injectables have unique properties that allow them to be formulated into doses suitable for injection. Many other common ARVs can’t be used in this way.
- The current suite of trials will provide information that could launch expanded trials in 2016/7 designed to test for efficacy and possible licensure for both treatment and prevention purposes.
<table>
<thead>
<tr>
<th>Product Name(s)</th>
<th>Phase of Research</th>
<th>Research Description</th>
<th>HIV Status of Population</th>
<th>Class of Drug</th>
<th>Location</th>
</tr>
</thead>
</table>
| **GSK744** (cabotegravir, GSK1265744) | Phase II | • Ongoing ECLAIR trial evaluating safety and tolerability of injections every 12 weeks in HIV-uninfected men in the US.  
• HPTN 077 evaluating the safety, tolerability and pharmacokinetics in HIV-uninfected men and women. | - | Integrase strand transfer inhibitor | Brazil, Malawi, South Africa (HPTN 077), US (HPTN 077 and ECLAIR) |
| **TMC278** (rilpivirine, Edurant) | Phase II | • Phase I trial evaluating the safety, acceptability, pharmacokinetics and pharmacodynamics of different dosing regimens underway in men and women in the US.  
• Phase II placebo-controlled HPTN 076 trial is evaluating safety, acceptability, drug presence in the genital tract of injections at eight week intervals among women in sub-Saharan Africa and the US and also gather information on HIV acquisition. | - | Nonnucleoside reverse transcriptase inhibitor | South Africa, US, Zimbabwe |
| **TMC278/GSK744** | Phase IIb | • A two-drug combination being tested as a "maintenance" regimen in people living with HIV who have achieved virologic suppression on triple-combination oral ARVs. | + | Nonnucleoside reverse transcriptase inhibitor plus integrase strand transfer inhibitor | Canada, France, Germany, Spain, US |
## Preventive Vaccines

<table>
<thead>
<tr>
<th>What is it?</th>
<th>What could it do?</th>
<th>Key Facts</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Seek to teach to the immune system how to protect itself against infection by a pathogen.</strong></td>
<td><strong>AIDS vaccines have been a key part of the prevention research agenda for nearly three decades.</strong>&lt;br&gt;<strong>Existing preventive vaccines for other diseases involve one or a series of immunizations, and can provide long-term or even lifelong protection.</strong>&lt;br&gt;<strong>Protection isn’t always complete and may wane over time.</strong>&lt;br&gt;<strong>The one AIDS vaccine strategy to show efficacy to date (in RV144) involved six immunizations and protection waned after one year.</strong>&lt;br&gt;<strong>Current research is focused on improving on these results as well as exploring other vaccine candidates entirely.</strong></td>
<td><strong>There is a robust pipeline of AIDS vaccine work, some of which overlaps with the investigations of passive immunization.</strong>&lt;br&gt;<strong>In Southern Africa, work continues on a suite of trials designed to build on the evidence from the RV144 trial.</strong>&lt;br&gt;<strong>A range of early-phase trials of other novel candidates to establish the safety and immunogenicity of other novel candidates are getting underway in 2015.</strong></td>
</tr>
</tbody>
</table>

---

*The list of clinical and preclinical trials below is not exhaustive. For details on full range of products in ongoing and completed trials, visit [avac.org](http://avac.org/pxrd).*
### Preventive Vaccines

<table>
<thead>
<tr>
<th>Product Name(s)</th>
<th>Phase of Research</th>
<th>Research Description</th>
<th>HIV Status of Population</th>
<th>Class of Drug</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ad26/MVA/gp140</strong></td>
<td>Phase I/II</td>
<td>• Trial testing safety and immunogenicity of various regimens containing Ad26 vector (a cold-causing virus, altered to not cause illness) and a “mosaic” immunogen, designed to induce immunity against a range of HIV subtypes.</td>
<td></td>
<td>Adenovirus 26/ Modified Vaccinia Ankara Mosaic/glycoprotein 140</td>
<td>South Africa, Thailand, US</td>
</tr>
</tbody>
</table>
| **ALVAC/AIDSVAX**                | Phase III follow-up and Phase I | • RV305 is taking place among participants from original RV144 trial to assess impact of additional boosts.  
• RV306 is testing the boosted regimen among new participants.                                                                 |                          | Pox-protein                                                                | Thailand                          |
| **ALVAC/gp120/ MF59 adjuvant Clade C** | Phase I/II       | • HVTN 100 is testing an RV144-like regimen that has been altered with goal of optimizing for southern Africa.  
• First trial in the “development track” of post-RV144 trials sponsored by the Pox-Protein Public-Private Partnership (P5). |                          | Pox-protein                                                                | South Africa                      |
| **ALVAC, DNA, Protein, MF59, AS01B adjuvant (various combinations)** | Phase I/II        | • Suite of trials in the P5 "research track" will evaluate various vaccine combinations to identify correlates of immunity that could improve future regimens. |                          | Pox-protein                                                                | Malawi, Mozambique, South Africa, Switzerland, Tanzania, US, Zambia, Zimbabwe |
New Frontiers in HIV Prevention, Treatment and Cure

Development of 3BNC117 Monoclonal antibody

Sarah J. Schlesinger
April 21, 2015
HIV-1 Treatment and Prevention - Challenges

- ART is highly effective, however **cannot eradicate** HIV-1 infection

- Despite substantial increase in coverage, **only 38% of adults and 24% children** in need are currently receiving ART (UNAIDS Report 2015)

- New infection rates remain high (**2.1 million in 2013**)

- Engagement in HIV-care remains a challenge (< **25% HIV+ with VL < 20 in the US**)

- An effective vaccine is not available – results from large efficacy phase 3 trials won’t be available until 2020

- A major challenge to an effective vaccine is the rapid establishment of a viral reservoir
  - Vaccines that block infection (sterilizing immunity)
B-Cell Lymphocytes

Antibody-producing cells of “bursal” origin. Produce immunoglobulin in response to antigen.
Antibody

Immunoglobulin produced by B-cells; may be neutralizing or non-neutralizing.
Passive Immunization is Effective against many Infectious Diseases

<table>
<thead>
<tr>
<th>Virus Pathogen</th>
<th>Passive Immunization leads to Protection</th>
<th>Vaccine Licensure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measles</td>
<td>Concentrated Human gamma globulin (Janeway, CA 1945)</td>
<td>1957</td>
</tr>
<tr>
<td>Polio</td>
<td>Red Cross gamma globulin (Hammon WM, 1953)</td>
<td>1954</td>
</tr>
<tr>
<td>Varicella</td>
<td>VZV-gamma globulin (Zaia JA, 1983)</td>
<td>1995</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>Hep B immune globulin (Beasley RP, 1983)</td>
<td>1984</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>Immune serum gamma globulin (Conrad ME, 1987)</td>
<td>1995</td>
</tr>
<tr>
<td>CMV</td>
<td>Polyclonal Ig for prophylaxis of transplant-associated infection (1990)</td>
<td>-</td>
</tr>
<tr>
<td>RSV</td>
<td>mAb (palivizumab) for prophylaxis of high risk infants (1998)</td>
<td>-</td>
</tr>
</tbody>
</table>

Adapted from Barney Graham
A fraction of HIV-1 infected individuals generate neutralizing antibody responses in 2-3 years post infection

- Single cell cloning methods allowed the isolation of new highly potent bNAbs

Adapted from Mouquet et al., Trends Immunol 2014
# Anti-HIV Antibodies Tested in Humans

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Target</th>
<th>Clinical Setting</th>
<th>Safety</th>
<th>Antiretroviral effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIVIGLOB</td>
<td>Polyclonal</td>
<td>Pregnant women and infants</td>
<td>Safe</td>
<td>p24 Ag cleared, no change in VL</td>
</tr>
<tr>
<td>F105 (Posner, 1998)</td>
<td>CD4 binding site</td>
<td>Viremic, on ART Single infusion</td>
<td>Safe</td>
<td>No effect by viral culture</td>
</tr>
<tr>
<td>2G12, 2F5 (Armbruster, 2002)</td>
<td>Carb epitope gp120 MPER gp41</td>
<td>Viremic (10K), ART naive</td>
<td>Safe</td>
<td>Transient reduction in VL (0.6 log)</td>
</tr>
<tr>
<td>4E10 and 4E10,2F5,2G12 (Armbruster, 2004)</td>
<td>Glycan gp120 MPER gp41</td>
<td>Viremic (100K), ART naive</td>
<td>Safe</td>
<td>No significant change in VL</td>
</tr>
<tr>
<td>2G12, 2F5, 4E10 (Trkola, 2005)</td>
<td>Glycan gp120 MPER gp41</td>
<td>ART interruption</td>
<td>Safe</td>
<td>Delay to viral rebound in few; 2G12 resistance</td>
</tr>
<tr>
<td>2G12, 2F5, 4E10 (Mehandru, 2007)</td>
<td>Glycan gp120 MPER gp41</td>
<td>ART interruption</td>
<td>Safe</td>
<td>Viral rebound in most; 2G12 resistance</td>
</tr>
<tr>
<td>KD-247 (Matsushita, 2015)</td>
<td>V3 loop</td>
<td>Viremic, ART naive</td>
<td>Safe</td>
<td>Transient VL reduction (0.6 log); V3 loop mutations</td>
</tr>
<tr>
<td>VRC01</td>
<td>CD4 binding site</td>
<td>HIV-infected, on/off ART Two doses, 1-40 mg/kg</td>
<td>Safe</td>
<td>Ongoing</td>
</tr>
</tbody>
</table>
Can new generation antibodies effectively control HIV-1 Infection?

A Combination of Five bNAbs Suppresses Viremia in hu-Mice

bNAb monotherapy led to transient decline in viremia followed by viral rebound. Rebounding viruses harbored escape mutations.
bNAbs in HIV-1 infected Hu-Mice and SHIV-infected NHP

Klein et al., Nature 2012; Horwitz et al., PNAS 2013; Shingai et al., 2013
Preclinical Evaluation of bNAB-mediated Therapy

• 3BNC117 can effectively suppress HIV-1 viremia in humanized mice, but there is rapid escape (Klein et al., Nature 2012; Horwitz et al., PNAS 2013)

• 3BNC117 can rapidly decrease viremia in NHPs and in most cases maintain suppression until mAb decays (Shingai et al., Nature 2013). Similar results were obtained with PGT121 and 10-1074 (Barouch D. et al., Shingai et al., Nature 2013)
Clinical Investigation of bNAb 3BNC117 (MCA-0835)

- Human monoclonal IgG1 k antibody
- Targets CD4bs on HIV-1 Env
- IC$_{80}$ on a combined group of 95 tier 2 viruses of 1.4 µg/ml
- 5 mg/kg was effective in protecting animals against intrarectal challenge in NHP
- 10 mg/kg induced rapid decline in plasma viremia (hu-mice, NHPs)

3BNC117

Scheid et al., Science 2011
Potential Clinical Applications of 3BNC117 and other HIV-1 NAbbs

- Prevention in high risk individuals
  - If favorable PK profile and potency in humans
  - If antibodies can be formulated for subcutaneous administration

- Adjuncts to conventional ART
  - In intensification regimens
  - During ART-interruption
  - Eradication strategies
3BNC117 – From the Lab to the Clinic First-in-Man Study

- Process development
- Pre-IND Mtg
- GMP manufacturing
- GLP Tox studies
- Tissue x-reactivity
- Prepare/submit IND
- Assay Validation/ Clinical Sample testing

- Completed Aug 2013
- Completed Oct 2013
- Submitted – Nov 20 2013

- FDA “Ok to proceed Letter” – Dec 19 2013
- Rockefeller IRB approval – Jan 14 2014
- First 3BNC117 infusion – Feb 12 2014
3BNC117 for Clinical Use
Protocol MCA-0835 - Study Objectives:

**Primary:**
Safety, tolerability and pharmacokinetics profile of a single intravenous infusion of 3BNC117 in HIV-infected and uninfected individuals

**Secondary:**
Effect of 3BNC117 on plasma HIV-1 RNA levels and the frequency and magnitude of induced anti-3BNC117 antibodies.

**Exploratory:**
Genotyping of escape variants that might arise, cell-associated HIV-1 RNA and DNA levels, 3BNC117 levels in cervicovaginal and rectal secretions, and HIV-1 specific T and B cell immune responses following administration of 3BNC117.
First-in-man Study of bNAb 3BNC117

Study Groups

HIV-negative

Group 1A: 1 mg/kg 1/3
Group 1B: 3 mg/kg 1/3
Group 1C: 10 mg/kg 1/3
Group 1E: 30 mg/kg 1/3

Additional groups
- 2 x 10 mg/kg (5/5)
- 2 x 30 mg/kg (3/3)

HIV-positive

Group 2A: 1 mg/kg 1/3
Group 2B: 1 mg/kg 1/3
Group 2C: 10 mg/kg 1/3
Group 2D/2E: 30 mg/kg 1/3

Additional groups
- 10 mg/kg, ART on (5/5)
- 30 mg/kg, ART off, <2,000 (1/5)
- 30 mg/kg, ART, VL >20 (4/5)
- 30 mg/kg, ART, VL 1-20 (2/5)
Study Design

3BNC117 infusion

Study Days:
- Screen
- Pre
- 0
- 1
- 2
- 4
- 7
- 14
- 21
- 28
- 42
- 56
- 84
- 112
- 140
- 168

- PK
- HIV-1 VL
- Sequencing
- CD4/CD8 counts
3BNC117 study – Enrollment and Safety

Enrollment
- 49 subjects enrolled
- 15 completed follow up

- 29 HIV-1-infected (16 off ART and 13 on ART)
- Baseline HIV-1 VL in subjects off ART: 640 – 53,470 cp/ml

Safety for subjects receiving 1, 3, 10, and 30 mg/kg
- No SAEs
- Well-tolerated; most reported AEs graded as mild (transient fatigue and headache)
3BNC117 Pharmacokinetics

<table>
<thead>
<tr>
<th></th>
<th>HIV-infected</th>
<th>HIV-uninfected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average</td>
<td>9.6 days</td>
<td>17.6 days</td>
</tr>
<tr>
<td>Half-life</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cmax</td>
<td>669.8</td>
<td>495.9</td>
</tr>
<tr>
<td>(30 mg/kg)</td>
<td>(410.2 - 976.4)</td>
<td>(360.8 - 765.0)</td>
</tr>
</tbody>
</table>
Summary – Safety and PK

• 3BNC117 has been generally safe and well tolerated at doses up to 30 mg/kg in HIV-uninfected and HIV-infected individuals, on and off ART.

• 3BNC117’s half-life is approximately 2.5 weeks in HIV-uninfected individuals. In viremic HIV-infected individuals, it is slightly shorter.
Single 3BNC117 infusion – Antiviral activity

1 mg/kg

HIV RNA (copies ml⁻¹)

Δlog₁₀ (copies ml⁻¹)

2A4
2A3
2A1

2B3
2B1

2C5
2C4

10 mg/kg
Single 3BNC117 infusion – Antiviral activity

30 mg/kg

HIV RNA (copies ml$^{-1}$) vs Days after infusion
Summary – Virologic Effects

• A single administration of 1 or 3 mg/kg led to small effects on plasma viremia but altered 3BNC117-sensitivity.

• A single administration of 30 mg/kg led to decline in plasma viremia in all individuals treated of up 2.5 logs (average 1.48 log). Plasma viremia remained significantly reduced for 28 days.

• Decline in viremia correlated with baseline sensitivity to 3BNC117 and to starting viral load.

• 3BNC117 selected resistant viral strains in some but not all viremic individuals treated.

• The long term effects on viremia and on host immune responses remain to be determined.
Future 3BNC117 studies

- Evaluate the effects of 3BNC117 on host immune responses (Florian Klein, Till Schoofs)
- Evaluate if 3BNC117 alters levels of CA-HIV-1 RNA and DNA (Josh Horwitz, Julio Lorenzi)

Future Clinical Studies:
- Can 3BNC117 prevent virologic rebound when ART is discontinued? (Johannes Scheid)
- Can 3BNC117 affect the size of the reservoir, alone or in combination with a latency reversing agent?
- Will 3BNC117 in combination 10-1074 lead to more significant effects on viremia (longer lasting)?
Balto

Central Park,
near East 67th Street
DEDICATED TO THE INDOMITABLE SPIRIT OF THE SLED DOGS THAT RAINED ANTITOXIN SIX HUNDRED MILES OVER ROUGH ICE ACROSS TREACHEROUS WATERS THROUGH ARCTIC BLIZZARDS FROM NENANA TO THE RELIEF OF STRICKEN Nome IN THE WINTER OF 1915.

ENDURANCE FIDELITY INTELLIGENCE
Acknowledgements

Study participants

**Lab. Molecular Immunology**
Michel Nussenzweig
Florian Klein
Julio Lorenzi
Malte Braunschweig
Lilian Nogueira
Johannes Scheid
Josh Horwitz
Ari Halper-Stromberg

**Clinical Vaccine Center**
Sarah Schlesinger
Noreen Buckley
Sonya Hadrigan
Maggi Pack
Sivan Ben Avraham Shulman
Irina Shimeliovich
Cecille Unson-O’Brien
Renise Baptiste
Amr Almaktari

**Celldex Therapeutics**
Tibor Keller
Tom Davis
Audrey Louie
Larry Thomas
Thomas Hawthorne

**The Rockefeller Univ Hospital**
Lauren Corregano
Inpatient and Outpatient Nursing Staff
Emil Gotschlich

**Caltech**
Pamela Bjorkman
Anthony West

**University of Cologne**
Gerd Faetkenheuer
Gisela Kremer

**WCMC**
Trip Gulick
Leah Burke

**MGH and Brigham and Women’s Hospital**
Lindsey Baden
Bruce Walker

**Bi-Deaconess/Harvard**
Mike Seaman

Support from the Bill and Melinda Gates Foundation, the Rockefeller University, HHMI
Acknowledgements